聚乙二醇干扰素与普通干扰素对慢性乙型肝炎患者外周血CD4+CD25highT淋巴细胞变化的影响

王海燕; 朱莉; 王银玲; 朱月萍; 朱晓燕; 柴晓哲; 钱峰; 李明; 朱传武

doi:10.3969/j.issn.1001-5256.2018.01.011

聚乙二醇干扰素与普通干扰素对慢性乙型肝炎患者外周血CD4+CD25highT淋巴细胞变化的影响

DOI: 10.3969/j.issn.1001-5256.2018.01.011

苏州市第五人民医院肝病科

基金项目:

苏州市科学技术局和苏州市卫生计生委兴卫基金项目(KJXW2011031)；苏州市临床重点病种诊疗技术项目(LCZX201315)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 473
- HTML全文浏览量: 25
- PDF下载量: 98
- 被引次数: 3
出版历程
- 出版日期: 2018-01-20

Impact of pegylated interferon versus conventional interferon on the change in peripheral CD4+CD25highT cells in patients with chronic hepatitis B

Department of Hepatology, The Fifth People′s Hospital of Suzhou, Suzhou, Jiangsu 215007, China

Research funding:

摘要

摘要:
目的比较聚乙二醇干扰素（PEG-IFNα-2a）与普通干扰素（IFNα-2b）抗病毒治疗对慢性乙型肝炎（CHB）患者外周血CD4+CD25highT淋巴细胞变化的影响。方法收集2012年6月-2015年6月于苏州市第五人民医院接受干扰素抗病毒治疗的HBeAg阳性CHB患者72例,按照患者自主选择的治疗方法分为PEG-IFNα-2a组（n=40）和IFNα-2b组（n=32）,干扰素抗病毒疗程至少1年。采集治疗前和治疗12个月时的抗凝外周静脉血。另选取同期30例健康人作为对照。用流式细胞技术检测外周血CD4+CD25highT淋巴细胞的百分率。符合正态分布的计量资料多组间比较采用单因素方差分析;不符合正态分布的计量资料两独立样本比较采用Mann-Whitney U检验,配对资料比较采用Wilcoxon秩和检验。计数资料组间比较采用χ2检验或Fisher确切检验。结果治疗12个月时,IFNα-2b组和PEG-IFNα-2a组的有效病例数分别为26例和32例。两组患者ALT复常率、H...
- 肝炎,乙型,慢性 /
- 干扰素α /
- T淋巴细胞,调节性
Abstract:
Objective To investigate the impact of pegylated interferon alpha-2 a ( PEG-IFNα-2 a) versus conventional interferon alpha-2 b ( IFNα-2 b) on the change in peripheral CD4+CD25high T cells in patients with chronic hepatitis B ( CHB) . Methods A total of 72 HBeAg-positive CHB patients who received interferon antiviral therapy in the Fifth People' s Hospital of Suzhou from June 2012 to June 2015 were enrolled, and according to the therapy selected by the patient, these patients were divided into PEG-IFNα-2 a group with 40 patients and IFNα-2 b group with 32 patients. The course of the interferon antiviral therapy was one year at least. The anticoagulant peripheral venous blood samples were collected before treatment and at month 12 of treatment. Another 30 healthy individuals were enrolled as controls. Flow cytometry was used to measure the percentage of peripheral CD4+CD25high T cells. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two independent samples; the Wilcoxon rank-sum test was used for comparison of paired data. The chi-square test or Fisher's exact test was used for comparison of categorical data between groups. Results At month 12 of treatment, there were 26 valid cases in the IFNα-2 b group and 32 valid cases in the PEG-IFNα-2 a group. There were no significant differences between the two groups in normalization rate of alanine aminotransferase, HBeAg seroconversion rate, and HBV DNA clearance rate ( P > 0. 05, P = 0. 05, P = 0. 47) . Before treatment, the IFNα-2 b group and the PEG-IFNα-2 a group had a significantly higher median percentage of peripheral CD4+CD25high T cells than the healthy control group ( U = 235. 5 and 238. 0, both P < 0. 05) . The PEG-IFNα-2 a group had a significant reduction in the median percentage of peripheral CD4+CD25high T cells at month 12 of interferon therapy ( Z =-2. 515, P = 0. 012) . As for the patients who achieved seroconversion of HBeAg, the IFNα-2 b group and the PEG-IFNα-2 a group had a significant reduction in peripheral CD4+CD25high T cells ( U = 121. 0 and 204. 5, both P < 0. 05) , while there was no significant difference between these two groups ( P > 0. 05) ; there was also no significant difference between these two groups and the healthy control group ( both P > 0. 05) . Conclusion Interferon antiviral therapy can reduce the percentage of peripheral CD4+CD25high T cells, and compared with IFNα-2 b, PEG-IFNα-2 a has a stronger effect in downregulating CD4+CD25high T cells; however, in patients who achieve seroconversion of HBeAg, PEG-IFNα-2 a and IFNα-2 b have a similar effect in downregulating CD4+CD25high T cells.
- hepatitis B, chronic /
- interferon-alpha /
- T-lymphocytes, regulatory

HTML全文

参考文献(23)

[1]HORI S, NOMURA T, SAKAGUCHI S.Control of regulatory T cell development by the transcription factor Foxp3[J].Science, 2003, 299 (5609) :1057-1061.

[2]STOOP JN, van der MOLEN RG, BAAN CC, et al.Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology, 2005, 41 (4) :771-778.

[3]FRANZESE O, KENNEDY PT, GEHRING AJ, et al.Modulation of the CD8+T-cell response by CD4+CD25+regulatory T cells in patients with hepatitis B virus infection[J].J Virol, 2005, 79 (6) :3322-3328.

[4]ROMAGNANI C, DELLA CHIESA M, KOHLER S, et al.Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+T helper cells and CD4+CD25hi T regulatory cells[J].Eur J Immunol, 2005, 35 (8) :2452-2458.

[5]AZUMA T, TAKAHASHI T, KUNISATO A, et al.Human CD4+CD25+regulatory T cells suppress NKT cell functions[J].Cancer Res, 2003, 63 (15) :4516-4520.

[6]TRZONKOWSKI P, SZMIT E, MY S'LIWSKA J, et al.CD4+CD25+T regulatory cells inhibit cytotoxic activity of T CD8+and NK lymphocytes in the direct cell-to-cell interaction[J].Clin Immunol, 2004, 112 (3) :258-267.

[7] LIM HW, HILLSAMER P, BANHAM AH, et al.Cutting edge:direct suppression of B cells by CD4+CD25+regulatory T cells[J].J Immunol, 2005, 175 (7) :4180-4183.

[8] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[9] European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol, 2017, 67 (2) :370-398.

[10]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[11]SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int, 2016, 10 (1) :1-98.

[12]SPRENGERS D, STOOP JN, BINDA RS, et al.Induction of regulatory T-cells and interleukin-10-producing cells in non-responders to pegylated interferon-alpha therapy for chronic hepatitis B[J].Antivir Ther, 2007, 12 (7) :1087-1096.

[13]PENG G, LI S, WU W, et al.Circulating CD4+CD25+regulatory T cells correlate with chronic hepatitis B infection[J].Immunology, 2008, 123 (1) :57-65.

[14]LI M, ZHUGE HX, ZHU CW, et al.The effects of CD4+CD25+high regulatory T cells in peripheral blood of patients with chronic hepatitis B on the hosts'immune function[J].Jiangsu Med J, 2007, 33 (9) :900-901. (in Chinese) 李明, 诸葛洪祥, 朱传武, 等.慢性乙型肝炎患者外周血CD4+CD25+high调节性T细胞对免疫状态的影响[J].江苏医药, 2007, 33 (9) :900-901.

[15]NAN XP, ZHANG Y, YU HT, et al.Inhibition of viral replication downregulates CD4 (+) CD25 (high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B[J].Viral Immunol, 2012, 25 (1) :21-28.

[16] NAN XP, ZHANG Y, YU HT, et al.Circulating CD4+CD25highregulatory T cells and expression of PD-1 and BTLA on CD4+T cells in patients with chronic hepatitis B virus infection[J].Viral Immunol, 2010, 23 (1) :63-70.

[17]HE JN, ZHAO SS.Research advances in association between regulatory T cells and hepatitis B virus infection[J].J Clin Hepatol, 2016, 32 (2) :361-365. (in Chinese) 何俊楠, 赵守松.调节性T淋巴细胞与HBV感染慢性化的关系[J].临床肝胆病杂志, 2016, 32 (2) :361-365.

[18]DENG Q, XIAO YQ, ZOU ZY, et al.The variation of CD4+CD25+Foxp3+regulatory T before and after antiviral therapy in chronic hepatitis B patients[J].Guangdong Med J, 33 (17) :2592-2595. (in Chinese) 邓茜, 肖影群, 邹正宇, 等.慢性乙型肝炎患者抗病毒治疗前后CD4+CD25+Foxp3+调节性T细胞的变化[J].广东医学, 33 (17) :2592-2595.

[19]QING KQ, YANG CG, LIU R.Analysis on the change of CD4+CD25+Foxp3+regulatory T cells in peripheral blood of patients with chronic hepatitis B[J].Lab Med, 2013, 28 (9) :811-814. (in Chinese) 卿克勤, 杨朝国, 刘蓉.慢性乙型肝炎患者外周血CD4+CD25+Foxp3+调节性T细胞变化水平及其与抗病毒疗效的关系[J].检验医学, 2013, 28 (9) :811-814.

[20]XU HT, XING TJ, LI H, et al.Association of T regulatory cells with natural course and response to treatment with interferon-αin patients with chronic hepatitis B infection[J].Chin Med J (Engl) , 2012, 125 (8) :1465-1468.

[21]LIU H.The curative effect of two drugs in the treatment of HBe Ag positive chronic hepatitis B and the forecast factors analysis of the serological conversion[J].J Clin Exp Med, 2017, 9 (16) :883-886. (in Chinese) 刘海.两种药物治疗HBe Ag阳性慢性乙型肝炎的疗效及血清学转换预测因素分析[J].临床和实验医学杂志, 2017, 9 (16) :883-886.

[22]MA H, ZHANG HH, WEI L.Frequency of T-cell Fox P3+Treg and CD4+/CD8+PD-1 expression is related to HBe Ag seroconversion in hepatitis B patients on pegylated interferon[J].Chin Med J (Engl) , 2013, 126 (2) :267-273.

[23]JIANG SL, TAN SZ, WEN J.Role of CD4+CD25+T regulatory cells in HBe Ag seroconversion during interferon antiviral[J].J Clin Hepatol, 2012, 28 (7) :528-530. (in Chinese) 蒋淑莲, 谭善忠, 文剑.干扰素治疗慢性乙型肝炎患者HBe Ag转阴率和CD4+CD25+调节性T细胞水平的关系[J].临床肝胆病杂志, 2012, 28 (7) :528-530.

施引文献